Maximize your thought leadership

Quantum BioPharma Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

By FisherVista•
Quantum BioPharma's improved liquidity and reduced expenses support its Phase 2 trial of Lucid-MS for progressive multiple sclerosis, potentially accelerating a new treatment for the disease.
Quantum BioPharma Reports $12.22 Million in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

Quantum BioPharma Ltd. (NASDAQ: QNTM) reported unaudited financial and operational results for the third quarter ended Sept. 30, 2026, highlighting improved liquidity, reduced operating expenses and progress in its clinical development program. The biopharmaceutical company, focused on neurodegenerative and metabolic disorders, said cash and cash equivalents totaled approximately $3.56 million, while digital assets reached $8.66 million, representing combined holdings of $12.22 million, compared with $4.12 million at year-end 2025, excluding restricted digital assets.

Shareholders’ equity increased 91% to $9.77 million, while working capital rose to $5.47 million from $420,000. Third-quarter operating expenses declined 24% year over year to $3.56 million, and the nine-month net loss narrowed 26% to $17.32 million from $23.25 million. The company also reported a 21% reduction in operating cash use for the first nine months of 2026 and a decrease in notes payable to $300,000 following repayment of $1 million in debt. Management stated that its cash and digital asset holdings are sufficient to support planned operations over the next 12 months.

Following quarter-end, Quantum entered into a study start-up agreement with the clinical research business of Thermo Fisher Scientific to implement its Phase 2 clinical trial of Lucid-MS for progressive multiple sclerosis. The agreement follows U.S. Food and Drug Administration clearance of the company’s Investigational New Drug application in August 2026. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

The news matters because multiple sclerosis is a chronic, often disabling disease of the central nervous system, and progressive forms have limited treatment options. Quantum BioPharma’s lead compound, Lucid-MS, aims to address myelin degradation, a root cause of MS. The Phase 2 trial, enabled by the Thermo Fisher agreement and FDA clearance, represents a critical step toward potential clinical proof-of-concept. For investors, the strengthened balance sheet, with $12.22 million in cash and digital assets and reduced cash burn, provides a runway to fund the trial and other operations over the next year without immediate financing pressure. For patients and the industry, a successful therapy could fill a significant unmet need in progressive MS.

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum is focused on the research and development of Lucid-MS. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights. For more details, the full press release is available at https://ibn.fm/GJ1ER, and the latest news and updates relating to QNTM can be found in the company’s newsroom at Quantum BioPharma (NASDAQ: QNTM).

The announcement was distributed through InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio at IBN, which provides editorial syndication to 5,000+ outlets. The platform also offers press release enhancement and social media distribution to maximize reach. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.

FisherVista

FisherVista

@fishervista